Aptose-Hanmi deal closing delayed to June pending Korean regulatory approvals
Aptose Biosciences announced that closing of its previously announced Plan of Arrangement with Hanmi Pharmaceutical has been further delayed due to pending Korean regulatory approvals, now targeted for June. The company received an additional US$2.0 million advance from Hanmi under a US$11.9 million loan facility to support continued operations of its TUSCANY clinical trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day